OR WAIT 15 SECS
Capsugel adds clinical trial and commercial manufacturing, as well as particle engineering services with two acquisitions.
In the latest development in a busy year of mergers and acquisitions in the contract services market, Capsugel announced on Dec. 14, 2015 that it has entered into an agreement to acquire Xcelience and Powdersize. Upon completion of the transaction, which is subject to regulatory approval, both Xcelience and Powdersize will be integrated with Capsugel’s Dosage Form Solutions business unit.
Xcelience (Tampa, Fla.) offers specialized clinical trial manufacturing and supply capabilities for a range of solid dosage forms. Powdersize (Quakertown, Pa.) offers micronization capabilities that will augment Capsugel’s formulation design services and bioavailability enhancement technology platform, according to a Capsugel press statement.
Capsugel reports that the acquisitions will expand the company’s services for clinical development, manufacturing, packaging, labeling and distribution services as well as commercial manufacturing capabilities; provide additional infrastructure for the handling of highly potent and controlled substances; add micro-dosing capabilities for powder-in-capsule evaluations and dissolution or stability challenges; and add particle-engineering expertise.
Terms of the transaction were not disclosed. Capsugel announced on Jan. 5, 216 that transaction was completed.
Updated on Jan. 5, 2016